Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00781 Entacapone [2] 6, 17
2 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00786 Tolcapone [3] 6, 28, 127
3 COMT [4] Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D10825 Opicapone [1] 6
4 MAPK14 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
5 MAPK14 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
6 DDC [6] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse D00558 Carbidopa [9] 2, 4, 6, 13, 17, 90, 140, 164, 201
7 DDC [6] Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse D03082 Benserazide [1] 6
8 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
9 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D00502 Pergolide [1] 6
10 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D00633 Dopamine [4] 6, 7, 74, 299
11 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D01044 Flupentixol [1] 97
12 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D02004 Apomorphine [3] 5, 6, 7
13 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D07460 Apomorphine [3] 5, 6, 7
14 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D07870 Dopamine [4] 6, 7, 74, 299
15 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D08339 Pergolide [1] 6
16 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D09886 Dexpramipexole [1] 2
17 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D11431 Tavapadon [1] 6
18 DRD1 [5] Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D11839 Foslevodopa [1] 6
19 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
20 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00136 Haloperidol [1] 8
21 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00270 Chlorpromazine [1] 254
22 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00426 Risperidone [5] 8, 156, 179, 187, 206
23 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00454 Olanzapine [2] 2, 8
24 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00458 Quetiapine [2] 6, 13
25 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00502 Pergolide [1] 6
26 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00559 Pramipexole [3] 2, 6, 20
27 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00560 Pimozide [1] 2
28 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00633 Dopamine [4] 6, 7, 74, 299
29 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00702 Buspirone [3] 6, 51, 179
30 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00726 Metoclopramide [1] 51
31 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00780 Bromocriptine [2] 6, 74
32 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00784 Ropinirole [4] 2, 6, 74, 309
33 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00789 Chlorpromazine [1] 254
34 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00799 Trifluoperazine [2] 283, 284
35 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00987 Cabergoline [3] 6, 74, 75
36 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01044 Flupentixol [1] 97
37 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01164 Aripiprazole [2] 6, 206
38 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01226 Sulpiride [5] 2, 6, 17, 46, 70
39 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01348 Terguride [2] 51, 86
40 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01448 Trifluoperazine [2] 283, 284
41 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01462 Lisuride [2] 6, 86
42 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01745 Domperidone [5] 6, 13, 17, 51, 230
43 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01898 Haloperidol [1] 8
44 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D02004 Apomorphine [3] 5, 6, 7
45 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D02213 Metoclopramide [1] 51
46 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D03165 Bromocriptine [2] 6, 74
47 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D03274 Chlorpromazine [1] 254
48 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D04034 Chlorpromazine [1] 254
49 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05008 Metoclopramide [1] 51
50 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05575 Pramipexole [3] 2, 6, 20
51 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05768 Rotigotine [2] 6, 127
52 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D06623 Olanzapine [2] 2, 8
53 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07305 Piribedil [1] 6
54 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07309 Melperone [1] 6
55 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07460 Apomorphine [3] 5, 6, 7
56 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07593 Buspirone [3] 6, 51, 179
57 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07868 Domperidone [5] 6, 13, 17, 51, 230
58 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07870 Dopamine [4] 6, 7, 74, 299
59 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08132 Lisuride [2] 6, 86
60 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08339 Pergolide [1] 6
61 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08456 Quetiapine [2] 6, 13
62 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08489 Ropinirole [4] 2, 6, 74, 309
63 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08549 Sulpiride [5] 2, 6, 17, 46, 70
64 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08590 Tiapride [1] 8
65 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08636 Trifluoperazine [2] 283, 284
66 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09397 Pardoprunox [1] 6
67 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09886 Dexpramipexole [1] 2
68 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09953 Pridopidine [3] 2, 6, 8
69 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09997 Cariprazine [1] 21
70 DRD2 [5] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D11839 Foslevodopa [1] 6
71 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
72 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine [2] 2, 8
73 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole [3] 2, 6, 20
74 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine [4] 6, 7, 74, 299
75 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole [4] 2, 6, 74, 309
76 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01164 Aripiprazole [2] 6, 206
77 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01462 Lisuride [2] 6, 86
78 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
79 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D06623 Olanzapine [2] 2, 8
80 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07305 Piribedil [1] 6
81 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
82 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
83 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
84 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09397 Pardoprunox [1] 6
85 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
86 DRD3 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
87 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
88 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00283 Clozapine [1] 6
89 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine [2] 2, 8
90 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole [3] 2, 6, 20
91 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine [4] 6, 7, 74, 299
92 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole [4] 2, 6, 74, 309
93 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D01462 Lisuride [2] 6, 86
94 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole [3] 2, 6, 20
95 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D06623 Olanzapine [2] 2, 8
96 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
97 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride [2] 6, 86
98 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole [4] 2, 6, 74, 309
99 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
100 DRD4 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
101 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa [8] 2, 4, 6, 17, 90, 140, 164, 201
102 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine [4] 6, 7, 74, 299
103 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine [4] 6, 7, 74, 299
104 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole [1] 2
105 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11431 Tavapadon [1] 6
106 DRD5 [2] Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa [1] 6
107 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
108 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
109 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
110 GRIA1 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
111 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
112 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
113 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
114 GRIA2 [10] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
115 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
116 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
117 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
118 GRIA3 [10] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
119 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
120 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
121 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
122 GRIA4 [7] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
123 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
124 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
125 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
126 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
127 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
128 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
129 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
130 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
131 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
132 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
133 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
134 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
135 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
136 GRIN2A [11] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
137 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
138 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
139 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine [4] 6, 8, 13, 127
140 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
141 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate [2] 6, 206
142 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
143 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
144 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine [7] 2, 6, 8, 13, 49, 127, 205
145 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
146 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
147 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
148 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
149 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [7] 2, 6, 8, 13, 49, 127, 205
150 GRIN2B [12] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
151 KCNJ3 [8] Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D00636 Amiodarone [2] 28, 127
152 KCNJ3 [8] Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D02910 Amiodarone [2] 28, 127
153 KCNJ5 [7] Retrograde endocannabinoid signaling, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D00636 Amiodarone [2] 28, 127
154 KCNJ5 [7] Retrograde endocannabinoid signaling, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D02910 Amiodarone [2] 28, 127
155 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D00505 Phenelzine [1] 6
156 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02561 Moclobemide [1] 6
157 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02579 Iproniazid [1] 6
158 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05458 Phentermine [1] 97
159 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05459 Phentermine [1] 97
160 MAOA [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08349 Phenelzine [1] 6
161 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D00505 Phenelzine [1] 6
162 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D00785 Selegiline [1] 6
163 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02562 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
164 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02579 Iproniazid [1] 6
165 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D03731 Selegiline [1] 6
166 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05458 Phentermine [1] 97
167 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05459 Phentermine [1] 97
168 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08349 Phenelzine [1] 6
169 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08469 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
170 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10158 Safinamide [2] 6, 17
171 MAOB [10] Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10829 Rasagiline [7] 2, 5, 6, 13, 17, 58, 66
172 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
173 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
174 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
175 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
176 PPP3CA [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
177 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
178 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
179 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
180 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
181 PPP3CB [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
182 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
183 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
184 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus [1] 160
185 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
186 PPP3CC [24] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin [1] 222
187 MAPK11 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
188 MAPK11 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
189 MAPK13 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
190 MAPK13 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
191 MAPK12 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod [2] 113, 222
192 MAPK12 [52] Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod [1] 8
193 SCN1A [1] Dopaminergic synapse D00252 Carbamazepine [2] 13, 231
194 SCN1A [1] Dopaminergic synapse D00354 Lamotrigine [5] 13, 34, 38, 114, 144
195 SCN1A [1] Dopaminergic synapse D00358 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
196 SCN1A [1] Dopaminergic synapse D00512 Phenytoin [1] 13
197 SCN1A [1] Dopaminergic synapse D00533 Oxcarbazepine [1] 13
198 SCN1A [1] Dopaminergic synapse D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
199 SCN1A [1] Dopaminergic synapse D00538 Zonisamide [1] 6
200 SCN1A [1] Dopaminergic synapse D00636 Amiodarone [2] 28, 127
201 SCN1A [1] Dopaminergic synapse D00638 Flecainide [1] 6
202 SCN1A [1] Dopaminergic synapse D00639 Mexiletine [5] 1, 2, 10, 113, 114
203 SCN1A [1] Dopaminergic synapse D00642 Quinidine [3] 2, 8, 13
204 SCN1A [1] Dopaminergic synapse D00643 Quinidine [3] 2, 8, 13
205 SCN1A [1] Dopaminergic synapse D01287 Levobupivacaine [1] 46
206 SCN1A [1] Dopaminergic synapse D01450 Bupivacaine [8] 46, 51, 53, 70, 96, 168, 226, 298
207 SCN1A [1] Dopaminergic synapse D01768 Oxybuprocaine [1] 6
208 SCN1A [1] Dopaminergic synapse D02086 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
209 SCN1A [1] Dopaminergic synapse D02103 Phenytoin [1] 13
210 SCN1A [1] Dopaminergic synapse D02272 Quinidine [3] 2, 8, 13
211 SCN1A [1] Dopaminergic synapse D02910 Amiodarone [2] 28, 127
212 SCN1A [1] Dopaminergic synapse D03492 Cibenzoline [1] 58
213 SCN1A [1] Dopaminergic synapse D04048 Ropivacaine [3] 36, 46, 70
214 SCN1A [1] Dopaminergic synapse D05775 Rufinamide [1] 144
215 SCN1A [1] Dopaminergic synapse D07552 Bupivacaine [8] 46, 51, 53, 70, 96, 168, 226, 298
216 SCN1A [1] Dopaminergic synapse D07962 Flecainide [1] 6
217 SCN1A [1] Dopaminergic synapse D08116 Levobupivacaine [1] 46
218 SCN1A [1] Dopaminergic synapse D08127 Lidocaine [13] 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
219 SCN1A [1] Dopaminergic synapse D08215 Mexiletine [5] 1, 2, 10, 113, 114
220 SCN1A [1] Dopaminergic synapse D08319 Oxybuprocaine [1] 6
221 SCN1A [1] Dopaminergic synapse D08458 Quinidine [3] 2, 8, 13
222 SCN1A [1] Dopaminergic synapse D08490 Ropivacaine [3] 36, 46, 70
223 SCN1A [1] Dopaminergic synapse D11155 Eleclazine [1] 58
224 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D00817 Bupropion [5] 8, 18, 21, 96, 171
225 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D01296 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
226 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D03215 Armodafinil [3] 6, 13, 84
227 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D04999 Methylphenidate [7] 6, 13, 34, 84, 113, 179, 206
228 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D05458 Phentermine [1] 97
229 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D05459 Phentermine [1] 97
230 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D07591 Bupropion [5] 8, 18, 21, 96, 171
231 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D07938 Bupropion [5] 8, 18, 21, 96, 171
232 SLC6A3 [4] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D08130 Lisdexamfetamine [1] 13
233 SLC18A2 [4] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08575 Tetrabenazine [1] 8
234 SLC18A2 [4] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10675 Valbenazine [1] 8
235 SLC18A2 [4] Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10701 Deutetrabenazine [1] 8
236 CACNA1B [12] MAPK signaling pathway, Synaptic vesicle cycle, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Type II diabetes mellitus, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Nicotine addiction D01173 Cilnidipine [1] 67
237 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
238 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
239 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
240 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
241 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
242 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine [2] 70, 86
243 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil [3] 96, 140, 167
244 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
245 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
246 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [3] 96, 140, 167
247 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
248 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
249 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline [2] 58, 272
250 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
251 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
252 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
253 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
254 CACNA1C [19] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226
255 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine [1] 6
256 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine [2] 50, 81
257 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
258 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine [4] 13, 51, 67, 298
259 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem [3] 51, 58, 86
260 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine [2] 70, 86
261 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil [3] 96, 140, 167
262 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine [1] 67
263 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine [1] 90
264 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil [3] 96, 140, 167
265 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine [4] 13, 51, 67, 298
266 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem [3] 51, 58, 86
267 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline [2] 58, 272
268 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine [4] 13, 51, 67, 298
269 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem [3] 51, 58, 86
270 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine [2] 70, 86
271 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline [2] 58, 272
272 CACNA1D [18] MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine [1] 226